-
1
-
-
84856002562
-
Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010
-
Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-213.
-
(2012)
Am J Ophthalmol
, vol.153
, pp. 209-213
-
-
Bloch, S.B.1
Larsen, M.2
Munch, I.C.3
-
2
-
-
84856023315
-
Time trends in the incidence and causes of blindness in Israel
-
Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012; 153: 214-221.
-
(2012)
Am J Ophthalmol
, vol.153
, pp. 214-221
-
-
Skaat, A.1
Chetrit, A.2
Belkin, M.3
Kinori, M.4
Kalter-Leibovici, O.5
-
3
-
-
84863882859
-
Visual impairment certification secondary to ARMD in Leeds, 2005-2010: Is the incidence falling?
-
Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Eye (Lond) 2012; 26: 933-936.
-
(2012)
Eye (Lond)
, vol.26
, pp. 933-936
-
-
Rostron, E.1
McKibbin, M.2
-
4
-
-
84882242958
-
Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK
-
Keenan TD, Kelly SP, Sallam A, Mohamed Q, Tufail A, Johnston RL et al. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 2013; 97: 1168-1172.
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 1168-1172
-
-
Keenan, T.D.1
Kelly, S.P.2
Sallam, A.3
Mohamed, Q.4
Tufail, A.5
Johnston, R.L.6
-
5
-
-
84887150456
-
Seven-year outcomes in ranibizumab-treated patients in ANCHOR MARINA and HORIZON: A multicenter cohort study (SEVEN-UP)
-
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299.
-
(2013)
Ophthalmology
, vol.120
, pp. 2292-2299
-
-
Rofagha, S.1
Bhisitkul, R.B.2
Boyer, D.S.3
Sadda, S.R.4
Zhang, K.5
-
6
-
-
84888005046
-
A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration
-
Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 2630-2636.
-
(2013)
Ophthalmology
, vol.120
, pp. 2630-2636
-
-
Rasmussen, A.1
Bloch, S.B.2
Fuchs, J.3
Hansen, L.H.4
Larsen, M.5
Lacour, M.6
-
7
-
-
70450201592
-
Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment
-
Amoaku W. Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment. Eye 2009; 23: 2140-2142.
-
(2009)
Eye
, vol.23
, pp. 2140-2142
-
-
Amoaku, W.1
-
8
-
-
84984932434
-
The royal college of ophthalmologists guidelines on AMD: Executive summary
-
Chakravarthy U, Williams M. The AMD Guidelines Group. The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. Eye 2013; 27: 1429-1431.
-
(2013)
Eye
, vol.27
, pp. 1429-1431
-
-
Chakravarthy, U.1
Williams, M.2
-
9
-
-
74549137478
-
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
-
Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13.
-
(2010)
Br J Ophthalmol
, vol.94
, pp. 2-13
-
-
Mitchell, P.1
Korobelnik, J.F.2
Lanzetta, P.3
Holz, F.G.4
Prünte, C.5
Schmidt-Erfurth, U.6
-
10
-
-
79955615679
-
Retreatment criteria in anti-VEGF therapy of exudative AMD: Critical analysis of present regimes and new morphological definition of "lesion activity"
-
Pauliekhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol 2011; 249: 631-632.
-
(2011)
Graefes Arch Clin Exp Ophthalmol
, vol.249
, pp. 631-632
-
-
Pauliekhoff, D.1
Kirchhof, B.2
-
11
-
-
84865721295
-
EVEREST study: Efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy
-
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST study: efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453-1464.
-
(2012)
Retina
, vol.32
, pp. 1453-1464
-
-
Koh, A.1
Lee, W.K.2
Chen, L.J.3
Chen, S.J.4
Hashad, Y.5
Kim, H.6
-
12
-
-
84875933604
-
Expert PCV Panel. Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment
-
Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A et al. Expert PCV Panel. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33: 686-716.
-
(2013)
Retina
, vol.33
, pp. 686-716
-
-
Koh, A.H.1
Chen, L.J.2
Chen, S.J.3
Chen, Y.4
Giridhar, A.5
-
13
-
-
84856134918
-
The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis)
-
Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2011; 109: 115-156.
-
(2011)
Trans Am Ophthalmol Soc
, vol.109
, pp. 115-156
-
-
Francis, P.J.1
-
14
-
-
84883806471
-
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
-
Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS et al. For The CATT Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013; 120: 1860-1870.
-
(2013)
Ophthalmology
, vol.120
, pp. 1860-1870
-
-
Jaffe, G.J.1
Martin, D.F.2
Toth, C.A.3
Daniel, E.4
Maguire, M.G.5
Ying, G.S.6
-
15
-
-
84885448955
-
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
-
Kitchens JW, Kassem N, Wood W, Stone TW, Isernhagen R, Wood E et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol 2013; 7: 1987-1993.
-
(2013)
Clin Ophthalmol
, vol.7
, pp. 1987-1993
-
-
Kitchens, J.W.1
Kassem, N.2
Wood, W.3
Stone, T.W.4
Isernhagen, R.5
Wood, E.6
-
16
-
-
84899934956
-
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group the neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections. Teport 1: Visual acuity
-
Tufail A, Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T et al. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections. teport 1: visual acuity. Ophthalmology 2014; 121: 1092-1101.
-
(2014)
Ophthalmology
, vol.121
, pp. 1092-1101
-
-
Tufail, A.1
Zarranz-Ventura, J.2
Liew, G.3
Johnston, R.L.4
Xing, W.5
Akerele, T.6
-
17
-
-
84908149389
-
The neovascular age-related macular degeneration database: Report 2. Incidence, management and visual outcomes of second treated eyes
-
Zarranz-Ventura J, Liew G, Johnston R, Tufail A, Xing W, Akerele T et al. The neovascular age-related macular degeneration database: report 2. Incidence, management and visual outcomes of second treated eyes. Ophthalmology 2014; 121: 1966-1975.
-
(2014)
Ophthalmology
, vol.121
, pp. 1966-1975
-
-
Zarranz-Ventura, J.1
Liew, G.2
Johnston, R.3
Tufail, A.4
Xing, W.5
Akerele, T.6
-
19
-
-
83455255286
-
Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12
-
Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye 2011; 25: 1617-1621.
-
(2011)
Eye
, vol.25
, pp. 1617-1621
-
-
Williams, T.A.1
Blyth, C.P.2
-
20
-
-
84859110467
-
Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration
-
Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153: 678-686.
-
(2012)
Am J Ophthalmol
, vol.153
, pp. 678-686
-
-
Lim, J.H.1
Wickremasinghe, S.S.2
Xie, J.3
Chauhan, D.S.4
Baird, P.N.5
Robman, L.D.6
-
21
-
-
84872026174
-
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
-
Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C et al. CATT Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 122-129.
-
(2013)
Ophthalmology
, vol.120
, pp. 122-129
-
-
Ying, G.S.1
Huang, J.2
Maguire, M.G.3
Jaffe, G.J.4
Grunwald, J.E.5
Toth, C.6
-
22
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
-
23
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
Soubrane, G.4
Heier, J.S.5
Kim, R.Y.6
-
24
-
-
57949094834
-
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
-
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
-
(2009)
Ophthalmology
, vol.116
, pp. 57-65
-
-
Brown, D.M.1
Michels, M.2
Kaiser, P.K.3
Heier, J.S.4
Sy, J.P.5
Ianchulev, T.6
-
25
-
-
84870723704
-
Intravitreal aflibercept (VEGF Trap-Eye) in wet are-related macular degeneration
-
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet are-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
-
(2012)
Ophthalmology
, vol.119
, pp. 2537-2548
-
-
Heier, J.S.1
Brown, D.M.2
Chong, V.3
Korobelnik, J.F.4
Kaiser, P.K.5
Nguyen, Q.D.6
-
26
-
-
75749133304
-
The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and disease model
-
Holz FG, Korobelnick JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51: 405-412.
-
(2010)
Invest Ophthalmol Vis Sci
, vol.51
, pp. 405-412
-
-
Holz, F.G.1
Korobelnick, J.F.2
Lanzetta, P.3
Mitchell, P.4
Schmidt-Erfurth, U.5
Wolf, S.6
-
27
-
-
79953295148
-
SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study
-
Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
-
(2011)
Ophthalmology
, vol.118
, pp. 663-671
-
-
Holz, F.G.1
Amoaku, W.2
Donate, J.3
Guymer, R.H.4
Kellner, U.5
Schlingemann, R.O.6
-
28
-
-
78049279239
-
Treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact
-
Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD et al. Treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117: 2134-2140.
-
(2010)
Ophthalmology
, vol.117
, pp. 2134-2140
-
-
Gupta, O.P.1
Shienbaum, G.2
Patel, A.H.3
Fecarotta, C.4
Kaiser, R.S.5
Regillo, C.D.6
-
29
-
-
84857446008
-
Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical and economic impact
-
Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. 2012; 153: e1.
-
(2012)
Am J Ophthalmol.
, vol.153
, pp. e1
-
-
Shienbaum, G.1
Gupta, O.P.2
Fecarotta, C.3
Patel, A.H.4
Kaiser, R.S.5
Regillo, C.D.6
-
30
-
-
85017808888
-
Early vs delayed 15-Letter responders to ranibizumab treatment in year 1 of the Phase III HARBOR Trial
-
Dreyer R, Kokame GT, Stoller G et al. Early vs delayed 15-Letter responders to ranibizumab treatment in year 1 of the Phase III HARBOR Trial. Invest Ophthalmol Vis Sci 2013; 54: 3829.
-
(2013)
Invest Ophthalmol Vis Sci
, vol.54
, pp. 3829
-
-
Dreyer, R.1
Kokame, G.T.2
Stoller, G.3
-
31
-
-
84888610071
-
Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration
-
Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013; 97: 1443-1446.
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 1443-1446
-
-
Krebs, I.1
Glittenberg, C.2
Ansari-Shahrezaei, S.3
Hagen, S.4
Steiner, I.5
Binder, S.6
-
32
-
-
38349172455
-
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
-
Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 239-248
-
-
Regillo, C.D.1
Brown, D.M.2
Abraham, P.3
Yue, H.4
Ianchulev, T.5
Schneider, S.6
-
33
-
-
79955631484
-
EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
-
Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R et al. EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
-
(2011)
Ophthalmology
, vol.118
, pp. 831-839
-
-
Schmidt-Erfurth, U.1
Eldem, B.2
Guymer, R.3
Korobelnik, J.F.4
Schlingemann, R.O.5
Axer-Siegel, R.6
-
34
-
-
84873867315
-
Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration
-
Hariprasad SM, Morse LS, Shapiro H, Wong P, Tuomi L. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol 2012; 2012: 690641.
-
(2012)
J Ophthalmol
, vol.2012
, pp. 690641
-
-
Hariprasad, S.M.1
Morse, L.S.2
Shapiro, H.3
Wong, P.4
Tuomi, L.5
-
35
-
-
85027955048
-
Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)
-
Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012; 32: 434-457.
-
(2012)
Retina
, vol.32
, pp. 434-457
-
-
Stewart, M.W.1
Rosenfeld, P.J.2
Penha, F.M.3
Wang, F.4
Yehoshua, Z.5
Bueno-Lopez, E.6
-
36
-
-
84873325259
-
Super-dose Anti-VEGF (SAVE): Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
-
Brown DM, Chen E, Mariani A, Major JC. Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013; 120: 349-354.
-
(2013)
Ophthalmology
, vol.120
, pp. 349-354
-
-
Brown, D.M.1
Chen, E.2
Mariani, A.3
Major, J.C.4
-
37
-
-
84875209738
-
For the CATT Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)
-
Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG et al. For The CATT Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013; 120: 593-599.
-
(2013)
Ophthalmology
, vol.120
, pp. 593-599
-
-
Hagstrom, S.A.1
Ying, G.S.2
Pauer, G.J.3
Sturgill-Short, G.M.4
Huang, J.5
Callanan, D.G.6
-
38
-
-
84887989386
-
For the IVAN Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study
-
Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA et al. For The IVAN Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology 2013; 120: 2637-2643.
-
(2013)
Ophthalmology
, vol.120
, pp. 2637-2643
-
-
Lotery, A.J.1
Gibson, J.2
Cree, A.J.3
Downes, S.M.4
Harding, S.P.5
Rogers, C.A.6
-
39
-
-
30944437438
-
Smoking and age-related macular degeneration: A review of association
-
Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP et al. Smoking and age-related macular degeneration: a review of association. Eye 2005; 19: 935-944.
-
(2005)
Eye
, vol.19
, pp. 935-944
-
-
Thornton, J.1
Edwards, R.2
Mitchell, P.3
Harrison, R.A.4
Buchan, I.5
Kelly, S.P.6
-
40
-
-
78649936436
-
Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis
-
Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
-
(2010)
BMC Ophthalmol
, vol.10
, pp. 31
-
-
Chakravarthy, U.1
Wong, T.Y.2
Fletcher, A.3
Piault, E.4
Evans, C.5
Zlateva, G.6
-
41
-
-
0031657921
-
Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat
-
Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998; 82: 1063-1071.
-
(1998)
Br J Ophthalmol
, vol.82
, pp. 1063-1071
-
-
Shen, W.Y.1
Yu, M.J.2
Barry, C.J.3
Constable, I.J.4
Rakoczy, P.E.5
-
42
-
-
0029758823
-
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes
-
Frank RN, Amin RH, Eliot D, Puklin JE, Abrams GW et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
-
(1996)
Am J Ophthalmol
, vol.122
, pp. 393-403
-
-
Frank, R.N.1
Amin, R.H.2
Eliot, D.3
Puklin, J.E.4
Abrams, G.W.5
-
43
-
-
0005581823
-
Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications
-
Frank RN. Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications. Ophthalmic Res 1997; 31: 243-244.
-
(1997)
Ophthalmic Res
, vol.31
, pp. 243-244
-
-
Frank, R.N.1
-
44
-
-
81555214460
-
Cytokines in neovascular age-related macular degeneration: Fundamentals of targeted combination therapy
-
Dias JR, Rodrigues EB, Maia M, Magalhães Jr O, Penha FM, Farah ME et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011; 95: 1631-1637.
-
(2011)
Br J Ophthalmol
, vol.95
, pp. 1631-1637
-
-
Dias, J.R.1
Rodrigues, E.B.2
Maia, M.3
Magalhães, Jr.O.4
Penha, F.M.5
Farah, M.E.6
-
45
-
-
56549111386
-
Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
-
Schaal S, Kaplan JG, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-2205.
-
(2008)
Ophthalmology
, vol.115
, pp. 2199-2205
-
-
Schaal, S.1
Kaplan, J.G.2
Tezel, T.H.3
-
46
-
-
58149190795
-
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
-
Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008; 14: 6371-6375.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6371-6375
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
47
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors
-
Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
-
(2005)
Cancer Cell
, vol.8
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
48
-
-
33846149645
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalises tumor vasculature and alleviates edema in glioblastoma patients
-
Batchelor TT, Sorenson AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalises tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
-
(2007)
Cancer Cell
, vol.11
, pp. 83-95
-
-
Batchelor, T.T.1
Sorenson, A.G.2
Di Tomaso, E.3
Zhang, W.T.4
Duda, D.G.5
Cohen, K.S.6
-
49
-
-
84867493598
-
Pilot study to evaLuate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrent macular fluid o30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)
-
Fung AT, Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS et al. Pilot study to evaLuate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrent macular fluid o30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye 2012; 26: 1181-1187.
-
(2012)
Eye
, vol.26
, pp. 1181-1187
-
-
Fung, A.T.1
Kumar, N.2
Vance, S.K.3
Slakter, J.S.4
Klancnik, J.M.5
Spaide, R.S.6
-
50
-
-
0000658715
-
Neurotransmission: The autonomic and somatic motor nervous systems
-
Goodman LS, Hardman JG, Limbird LE et al. (eds). 10th edn. McGraw-Hill: New York, NY, USA
-
Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman LS, Hardman JG, Limbird LE et al. (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York, NY, USA, 2001; 115-154.
-
(2001)
Goodman and Gilman's the Pharmacological Basis of Therapeutics
, pp. 115-154
-
-
Hoffman, B.B.1
Taylor, P.2
-
51
-
-
33645061248
-
Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients
-
Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006; 60: 415-421.
-
(2006)
Int J Clin Pract
, vol.60
, pp. 415-421
-
-
Tsagaraki, V.1
Amfilochiou, A.2
Markantonis, S.L.3
-
52
-
-
3042781690
-
The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter
-
Brown SM, Khanani AM, McCartney DL. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Am J Ophthalmol 2004; 138: 149-151.
-
(2004)
Am J Ophthalmol
, vol.138
, pp. 149-151
-
-
Brown, S.M.1
Khanani, A.M.2
McCartney, D.L.3
-
53
-
-
36448985258
-
Monitoring patients treated with anti-TNFalpha biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies
-
Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNFalpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-1834.
-
(2007)
Rheumatology
, vol.46
, pp. 1828-1834
-
-
Svenson, M.1
Geborek, P.2
Saxne, T.3
Bendtzen, K.4
-
54
-
-
48249144751
-
Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration
-
Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3115-3120.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 3115-3120
-
-
Keane, P.A.1
Liakopoulos, S.2
Ongchin, S.C.3
Heussen, F.M.4
Msutta, S.5
Chang, K.T.6
-
55
-
-
65349118184
-
Bevacizumab tachyphylaxis
-
author reply 1017
-
Falavarjani KG, Modarres M. Bevacizumab tachyphylaxis. Ophthalmology 2009; 116: 1016-1017 author reply 1017.
-
(2009)
Ophthalmology
, vol.116
, pp. 1016-1017
-
-
Falavarjani, K.G.1
Modarres, M.2
-
56
-
-
67749106387
-
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration
-
Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.
-
(2009)
Retina
, vol.29
, pp. 723-731
-
-
Forooghian, F.1
Cukras, C.2
Meyerle, C.B.3
Chew, E.Y.4
Wong, W.T.5
-
58
-
-
80052547257
-
Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab
-
Almony A, Mansouri A, Shah GK, Blinder KJ. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 2011; 46: 182-185.
-
(2011)
Can J Ophthalmol
, vol.46
, pp. 182-185
-
-
Almony, A.1
Mansouri, A.2
Shah, G.K.3
Blinder, K.J.4
-
59
-
-
84455206370
-
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
-
Gasperini RL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96: 14-20.
-
(2012)
Br J Ophthalmol
, vol.96
, pp. 14-20
-
-
Gasperini, R.L.1
Fawzi, A.A.2
Khondkaryan, A.3
Lam, L.4
Chong, L.P.5
Eliott, D.6
-
60
-
-
84455204035
-
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
-
Eghoj MS, Sorenson TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96: 21-23.
-
(2012)
Br J Ophthalmol
, vol.96
, pp. 21-23
-
-
Eghoj, M.S.1
Sorenson, T.L.2
-
61
-
-
84879235232
-
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
-
Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22.
-
(2013)
Am J Ophthalmol
, vol.156
, pp. 15-22
-
-
Bakall, B.1
Folk, J.C.2
Boldt, H.C.3
Sohn, E.H.4
Stone, E.M.5
Russell, S.R.6
-
62
-
-
84880005310
-
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
-
Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035.
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 1032-1035
-
-
Cho, H.1
Shah, C.P.2
Weber, M.3
Heier, J.S.4
-
63
-
-
84879203732
-
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration
-
Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35.
-
(2013)
Am J Ophthalmol
, vol.156
, pp. 29-35
-
-
Yonekawa, Y.1
Andreoli, C.2
Miller, J.B.3
Loewenstein, J.I.4
Sobrin, L.5
Eliott, D.6
-
64
-
-
84883740682
-
Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
-
Kumar N, Mansouri A, Shah GK, Fung AT, Slakter J, Sorenson J et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
-
(2013)
Retina
, vol.33
, pp. 1605-1612
-
-
Kumar, N.1
Mansouri, A.2
Shah, G.K.3
Fung, A.T.4
Slakter, J.5
Sorenson, J.6
-
65
-
-
84922391789
-
Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
-
Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye 2014; 28: 538-545.
-
(2014)
Eye
, vol.28
, pp. 538-545
-
-
Ehlken, C.1
Jungmann, S.2
Bohringer, D.3
Agostini, H.T.4
Junker, B.5
Pielen, A.6
-
66
-
-
79958748965
-
A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications
-
Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye (Lond) 2011; 25: 710-716.
-
(2011)
Eye (Lond)
, vol.25
, pp. 710-716
-
-
Kelly, S.P.1
Barua, A.2
-
67
-
-
21744461121
-
Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration
-
Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005; 40: 313-319.
-
(2005)
Can J Ophthalmol
, vol.40
, pp. 313-319
-
-
Oliver-Fernandez, A.1
Bakal, J.2
Segal, S.3
Shah, G.K.4
Dugar, A.5
Sharma, S.6
-
68
-
-
60149107965
-
Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss
-
Arias L, Armadá F, Donate J, García-Arumí J, Giralt J, Pazos B et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009; 23: 326-333.
-
(2009)
Eye
, vol.23
, pp. 326-333
-
-
Arias, L.1
Armadá, F.2
Donate, J.3
García-Arumí, J.4
Giralt, J.5
Pazos, B.6
-
69
-
-
79952993616
-
Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis): The key to success
-
Matthe E, Sandner D. Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis): the key to success. Ophthalmologe 2011; 108: 237-243.
-
(2011)
Ophthalmologe
, vol.108
, pp. 237-243
-
-
Matthe, E.1
Sandner, D.2
-
70
-
-
79955590384
-
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity
-
Muether PS, Hermann MM, Koch K, Fauser S. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011; 249: 633-637.
-
(2011)
Graefes Arch Clin Exp Ophthalmol
, vol.249
, pp. 633-637
-
-
Muether, P.S.1
Hermann, M.M.2
Koch, K.3
Fauser, S.4
-
71
-
-
36249002808
-
Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results
-
Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 850-857
-
-
Kaiser, P.K.1
Brown, D.M.2
Zhang, K.3
Hudson, H.L.4
Holz, F.G.5
Shapiro, H.6
-
72
-
-
84930837030
-
-
EURETINA Congress: Hamburg Germany
-
Awad M, Amoaku W, Yang Y, Chong V, Alsop J. Early visual acuity (VA) gains with ranibizumab are predictive of good long-term VA outcomes in wet age-related macular degeneration (wAMD) -a sub-analysis of the EXCITE study. EURETINA Congress: Hamburg, Germany, 2013.
-
(2013)
Early Visual Acuity (VA) Gains with Ranibizumab Are Predictive of Good Long-term VA Outcomes in Wet Age-related Macular Degeneration (WAMD) -A Sub-analysis of the EXCITE Study
-
-
Awad, M.1
Amoaku, W.2
Yang, Y.3
Chong, V.4
Alsop, J.5
-
73
-
-
84930852368
-
-
EURETINA Congress: Hamburg Germany
-
Amoaku WM, Yang Y, Chong V, Brittain C, Alsop J, Osborne A et al. Durability of visual acuity responses to ranibizumab in wet age-related macular degeneration patients of the EXCITE Study. EURETINA Congress: Hamburg, Germany, 2013.
-
(2013)
Durability of Visual Acuity Responses to Ranibizumab in Wet Age-related Macular Degeneration Patients of the EXCITE Study
-
-
Amoaku, W.M.1
Yang, Y.2
Chong, V.3
Brittain, C.4
Alsop, J.5
Osborne, A.6
-
74
-
-
84891631034
-
Intravitreal Aflibercept injection for neovascular age-related macular degeneration: Ninety-Six-Week results of the VIEW Studies
-
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V. Intravitreal Aflibercept injection for neovascular age-related macular degeneration: Ninety-Six-Week results of the VIEW Studies. Ophthalmology 2014; 121: 193-201.
-
(2014)
Ophthalmology
, vol.121
, pp. 193-201
-
-
Schmidt-Erfurth, U.1
Kaiser, P.K.2
Korobelnik, J.F.3
Brown, D.M.4
Chong, V.5
-
75
-
-
78651371501
-
Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration
-
Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011; 31: 26-30.
-
(2011)
Retina
, vol.31
, pp. 26-30
-
-
Oubraham, H.1
Cohen, S.Y.2
Samimi, S.3
Marotte, D.4
Bouzaher, I.5
Bonicel, P.6
-
76
-
-
84876971026
-
Current anti-vascular endothelial growth factor dosing regimens: Benefits and burden
-
Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013; 120: S3-S7.
-
(2013)
Ophthalmology
, vol.120
, pp. S3-S7
-
-
Haller, J.A.1
-
77
-
-
84887134639
-
Ranibizumab for exudative AMD in a clinical setting: Differences between 2007 and 2010
-
Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahaye-Mazza C, Fajnkuchen F et al. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2499-2503.
-
(2013)
Graefes Arch Clin Exp Ophthalmol
, vol.251
, pp. 2499-2503
-
-
Cohen, S.Y.1
Dubois, L.2
Ayrault, S.3
Dourmad, P.4
Delahaye-Mazza, C.5
Fajnkuchen, F.6
|